<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708444</url>
  </required_header>
  <id_info>
    <org_study_id>CD318 in AML</org_study_id>
    <nct_id>NCT04708444</nct_id>
  </id_info>
  <brief_title>Prognostic Value of CD318 in AML at Assiut University Hospital.</brief_title>
  <official_title>Prognostic Value of CD318 in Acute Myeloid Leukemia Patients at Assiut University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shimaa Arafa Ibrahim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will focus on the prognostic value of CD318 in acute myeloid leukemia patients at Assiut&#xD;
      University Hospital&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myeloid leukemia (AML) is a disease with high mortality and variable prognosis . It&#xD;
      remains a disease with a highly variable outcome depending on the exact footprint of the AML&#xD;
      .Although many patients with AML have a response to induction therapy ,refractory disease is&#xD;
      common and relapse represents the major cause of treatment failure .In 2016 the World Heath&#xD;
      Organization published revisions to classification of Myeloid Neoplasms and Acute leukemias&#xD;
      .Well-established prognostic factors are cytogenetic aberrations such as t(8;21), inv(16),&#xD;
      and t(15;17) as well as mutated IDH1/2, NPM1, and FLT3 genes but only few markers can&#xD;
      specifically predict the outcome after HSCT .Immunophenotyping via flowcytometry comprises an&#xD;
      additional fast technique to predict outcome in AML, although only few markers are yet&#xD;
      established as prognostic factors in clinical routine diagnosis, despite the fact that new&#xD;
      and rapidly available markers are needed to improve the treatment decisions in AML patients.&#xD;
      This is even more since starting therapy in AML patients must be initiated immediately after&#xD;
      diagnosis . Overall mortality from AML is high and treatment should be initiated within hours&#xD;
      after first diagnosis . In hematopoietic cells,CD318 has been identified as stem cell marker&#xD;
      for both benign and malignant progenitor cells. CD318+ bone marrow or cord blood-derived&#xD;
      cells have been shown to be capable to initiate multi-lineage hematopoiesis in vitro and in&#xD;
      vivo .CD318 (CUB domain containing protein-1, CDCP1) is a highly glycosylated single pass&#xD;
      transmembrane protein express endomesenchymal and neural stem cells and fibroblasts and&#xD;
      hematopoietic.Overexpression of CD318 has been recently correlated with poor overall&#xD;
      survival(OS) in colonic ,breast ,renal, hepatocellular ,and pancreatic Carcinoma.possibly due&#xD;
      to its role in metastasis formation via interaction with integrins and anti-apoptotic&#xD;
      signaling via Akt. Of AML blasts, pronounced CD318 expression has been observed on the&#xD;
      immature CD34+CD133+ leukemic cells subset implicated to be enriched for leukemic stem.&#xD;
      However, the impact of CD318 on survival in hematological malignancies has so far not been&#xD;
      analyzed. Study done by Jonas S et al showed 57% of AML patients expressed relevant CD318&#xD;
      levels and a significant correlation of CD 318 surface levels with prognosis was observed .&#xD;
      In our study investigators will use flowcytometry to detect CD318 on AML blasts and correlate&#xD;
      it with disease course and outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognosis of CD318 in AML</measure>
    <time_frame>Throughout study completion, average of one year</time_frame>
    <description>Flowcytometric analysis of AML blasts for CD318 and correlate it with disease course (progression free survival) and disease outcome (overall survival) . Also correlate level of expression of CD318 with response to treatment given ( intensive chemotherapy, hypomethylating agents, alternative palliative therapy.&#xD;
CD318 to detect level of expression and correlate it with disease course (progression free survival) and outcome (overall survival) .</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CD318</intervention_name>
    <description>Flowcytometric marker</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        our study will include newly diagnosed AML patients at clinical hematology unit Assiut&#xD;
        University during the period from March 2021 to August 2022. The diagnosis and&#xD;
        classification of AML relied on morphology and cytochemistry of bone marrow according to&#xD;
        FAB classification. patients will be subjected to full history taking clinical examination&#xD;
        laboratory investigations CBC,LFTs,RFTs,electrolytes,ESR,LDH,CRP,Coagulationprofile,aptt&#xD;
        ,fibrinogen, D dimer, bone marrow assessment with immunephenotyping and cytogenetic&#xD;
        analysis.&#xD;
&#xD;
        Flowcytometric analysis of AML blasts for CD 318&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. newly diagnosed AML patients&#xD;
&#xD;
          2. Age more than 18 years&#xD;
&#xD;
          3. Patients not starting chemotherapy yet&#xD;
&#xD;
          4. Primary AML&#xD;
&#xD;
          5. Secondary AML on top of MDS or myeloproliverative noeplasms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refractory AML patients&#xD;
&#xD;
          2. Relapsed AML patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998 Oct 1;92(7):2322-33.</citation>
    <PMID>9746770</PMID>
  </reference>
  <reference>
    <citation>Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH; Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001 Sep 1;98(5):1312-20.</citation>
    <PMID>11520776</PMID>
  </reference>
  <reference>
    <citation>Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001 Sep 15;98(6):1752-9.</citation>
    <PMID>11535508</PMID>
  </reference>
  <reference>
    <citation>Conze T, Lammers R, Kuci S, Scherl-Mostageer M, Schweifer N, Kanz L, Buhring HJ. CDCP1 is a novel marker for hematopoietic stem cells. Ann N Y Acad Sci. 2003 May;996:222-6.</citation>
    <PMID>12799299</PMID>
  </reference>
  <reference>
    <citation>Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene. 2001 Jul 19;20(32):4402-8.</citation>
    <PMID>11466621</PMID>
  </reference>
  <reference>
    <citation>Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene. 2003 Mar 27;22(12):1783-94.</citation>
    <PMID>12660814</PMID>
  </reference>
  <reference>
    <citation>Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene. 2014 Jan 9;33(2):255-68. doi: 10.1038/onc.2012.547. Epub 2012 Dec 3.</citation>
    <PMID>23208492</PMID>
  </reference>
  <reference>
    <citation>Liersch R, Müller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. Br J Haematol. 2014 Apr;165(1):17-38. doi: 10.1111/bjh.12750. Epub 2014 Feb 1. Review.</citation>
    <PMID>24484469</PMID>
  </reference>
  <reference>
    <citation>Uekita T, Fujii S, Miyazawa Y, Iwakawa R, Narisawa-Saito M, Nakashima K, Tsuta K, Tsuda H, Kiyono T, Yokota J, Sakai R. Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis. Mol Cancer Res. 2014 Oct;12(10):1449-59. doi: 10.1158/1541-7786.MCR-13-0587. Epub 2014 Jun 17.</citation>
    <PMID>24939643</PMID>
  </reference>
  <reference>
    <citation>Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Montemurro F, Catapano C, Bertoni F, Alimonti A. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell Rep. 2015 Apr 28;11(4):564-76. doi: 10.1016/j.celrep.2015.03.044. Epub 2015 Apr 16.</citation>
    <PMID>25892239</PMID>
  </reference>
  <reference>
    <citation>Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184. Review.</citation>
    <PMID>26376137</PMID>
  </reference>
  <reference>
    <citation>Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8.</citation>
    <PMID>26351297</PMID>
  </reference>
  <reference>
    <citation>Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11. Review.</citation>
    <PMID>27069254</PMID>
  </reference>
  <reference>
    <citation>De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016 Jul 1;6(7):e441. doi: 10.1038/bcj.2016.50. Review.</citation>
    <PMID>27367478</PMID>
  </reference>
  <reference>
    <citation>Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.</citation>
    <PMID>27895058</PMID>
  </reference>
  <reference>
    <citation>Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):E6912-E6921. doi: 10.1073/pnas.1704008114. Epub 2017 Jul 31.</citation>
    <PMID>28760953</PMID>
  </reference>
  <reference>
    <citation>Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018 Oct;93(10):1267-1291. doi: 10.1002/ajh.25214. Review.</citation>
    <PMID>30328165</PMID>
  </reference>
  <reference>
    <citation>Heitmann JS, Hagelstein I, Hinterleitner C, Roerden M, Jung G, Salih HR, Märklin M, Kauer J. Identification of CD318 (CDCP1) as novel prognostic marker in AML. Ann Hematol. 2020 Mar;99(3):477-486. doi: 10.1007/s00277-020-03907-9. Epub 2020 Jan 21.</citation>
    <PMID>31965270</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shimaa Arafa Ibrahim</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

